Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office Jan 24, 2023
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results Jan 6, 2023
Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference Jan 4, 2023
Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals Jan 3, 2023
Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis Nov 30, 2022
Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022 Oct 28, 2022
